Flagship Pioneering, LLC Long-Term Concentrated

Location: Cambridge, MA

CIK: 0001400240 · Show all filings

Period: Q4 2017 (← Previous) (Next →)

Filing Date: Feb 14, 2018

Total Value: $394M (100.0% shares, 0.0% debt)

Holdings (5)

DNLI DENALI THERAPEUTICS INC 35.4%

Value $139M Shares 8,918,749 Est. Cost $17.97 Unrealized 0.0%

— SERES THERAPEUTICS INC 32.6%

Value $129M Shares 12,682,876 Est. Cost $12.29 Unrealized —

EDIT EDITAS MEDICINE INC 13.0%

Value $51.45M Shares 1,674,435 Est. Cost $20.49 Unrealized +22.9%

QTRX QUANTERIX CORP 11.1%

Value $43.59M Shares 2,030,495 Est. Cost $19.52 Unrealized 0.0%

— SYROS PHARMACEUTICALS INC 7.9%

Value $31.18M Shares 3,204,437 Est. Cost $13.87 Unrealized —

Ticker	Issuer	Shares	Value	%	Est. Cost	Unrealized	Class	CUSIP
DNLI	DENALI THERAPEUTICS INC	8,918,749	$139M	35.4%	$17.97	0.0%	COM	24823R105
—	SERES THERAPEUTICS INC	12,682,876	$129M	32.6%	$12.29	—	COM	81750R102
EDIT	EDITAS MEDICINE INC	1,674,435	$51.45M	13.0%	$20.49	+22.9%	COM	28106W103
QTRX	QUANTERIX CORP	2,030,495	$43.59M	11.1%	$19.52	0.0%	COM	74766Q101
—	SYROS PHARMACEUTICALS INC	3,204,437	$31.18M	7.9%	$13.87	—	COM	87184Q107